胰升糖素样肽1药物对2型糖尿病患者的心血管保护效应  

Cardiovascular protective effects of glucagon-like peptide-1 agents in patients with type 2 diabetes

作　　者：柯静[1] 魏蕊[1] 洪天配[1] 

机构地区：[1]北京大学第三医院内分泌科,100191

出　　处：《中华内分泌代谢杂志》2015年第9期812-815,共4页Chinese Journal of Endocrinology and Metabolism

基　　金：国家自然科学基金资助项目（81270858,81401142,81400767,81400798）;高等教育博士学科点新教师基金资助项目（20120001120069,20120001120076）

摘　　要：胰升糖素样肽1（GLP-1）药物在2型糖尿病患者的血糖控制中具有重要作用。此外,GLP-1药物还具有一定的心血管保护效应,其可改善血管内皮功能,缓解肥胖、高血糖、血脂异常、高血压等心血管危险因素,延缓动脉粥样硬化的发生和发展,改善心肌缺血-再灌注损伤和心力衰竭。因此,GLP-1药物在心血管疾病发生发展的不同阶段和环节中可能具有保护作用。[Summary] Glucagon-like peptide-1 （ GLP-1 ） agents play important roles in glycemic control in type 2 diabetes. Moreover, these agents also show various protective effects on cardiovascular system. GLP-1 agents improve vascular endothelial function, ameliorate the risk factors of cardiovascular disease including obesity, hyperglycemia, dyslipidemia and hypertension, delay the occurrence and progression of atherosclerosis, and protect against cardiac ischemia-reperfusion injury and heart failure. Therefore, GLP-1 agents may have beneficial effects on cardiovascular diseases at different stages and in multiple aspects.

关 键 词：胰升糖素样肽1 糖尿病 2型 心血管疾病 

分 类 号：R587.1[医药卫生—内分泌]